InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,127.79
(
1.26%
)
US TECH 100
17,446.00
(
2.17%
)
Dow Jones
38,675.68
(
1.18%
)
Brent Oil
82.77
(
0.00%
)
Bitcoin
63,849.45
(
-0.07%
)
Post# of 251715
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

loparn

Send PM Follow Ignore
Followers 0
Posts 54
Boards Moderated 0
Alias Born 04/25/2011

loparn

Re: None

Sunday, 10/23/2016 2:06:55 PM

Sunday, October 23, 2016 2:06:55 PM

Post# of 251715
The Swedish biotech company WntResearch has a very promising drug candidate Foxy-5 targeting the lethal process of metastasis which accounts for around 90 % of the deaths in cancer. The focus is on breast, colon and prostate cancer. According to my valuation the WNT stock has a fundamental risk adjusted value of some 15-25 times the current value at the Swedish list "Aktietorget".

I have made a very short English version of my extremely long Swedish analysis :

http://www.infoom.se/mysite/index.php?sida=80579&user=9801


You can also read about WNT.ST on their home page http://www.wntresearch.com
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up